More than 95% of patients with CML are Philadelphia (Ph) positive with reciprocal translocation t(9;22)(q34;q11) generating BCR-ABL1 fusion protein with constitutive tyrosine kinase (TK) activity [2,3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.